Skip to main content
Journal cover image

Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol.

Publication ,  Journal Article
Cohen, JB; Hanff, TC; Corrales-Medina, V; William, P; Renna, N; Rosado-Santander, NR; Rodriguez-Mori, JE; Spaak, J; Andrade-Villanueva, J ...
Published in: J Clin Hypertens (Greenwich)
October 2020

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19), is associated with high incidence of multiorgan dysfunction and death. Angiotensin-converting enzyme 2 (ACE2), which facilitates SARS-CoV-2 host cell entry, may be impacted by angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), two commonly used antihypertensive classes. In a multicenter, international randomized controlled trial that began enrollment on March 31, 2020, participants are randomized to continuation vs withdrawal of their long-term outpatient ACEI or ARB upon hospitalization with COVID-19. The primary outcome is a hierarchical global rank score incorporating time to death, duration of mechanical ventilation, duration of renal replacement or vasopressor therapy, and multiorgan dysfunction severity. Approval for the study has been obtained from the Institutional Review Board of each participating institution, and all participants will provide informed consent. A data safety monitoring board has been assembled to provide independent oversight of the project.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Hypertens (Greenwich)

DOI

EISSN

1751-7176

Publication Date

October 2020

Volume

22

Issue

10

Start / End Page

1780 / 1788

Location

United States

Related Subject Headings

  • Withholding Treatment
  • Vasoconstrictor Agents
  • Severity of Illness Index
  • SARS-CoV-2
  • Respiration, Artificial
  • Renal Replacement Therapy
  • Prospective Studies
  • Multiple Organ Failure
  • Male
  • Incidence
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cohen, J. B., Hanff, T. C., Corrales-Medina, V., William, P., Renna, N., Rosado-Santander, N. R., … Chirinos, J. A. (2020). Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol. J Clin Hypertens (Greenwich), 22(10), 1780–1788. https://doi.org/10.1111/jch.14011
Cohen, Jordana B., Thomas C. Hanff, Vicente Corrales-Medina, Preethi William, Nicolas Renna, Nelson R. Rosado-Santander, Juan E. Rodriguez-Mori, et al. “Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol.J Clin Hypertens (Greenwich) 22, no. 10 (October 2020): 1780–88. https://doi.org/10.1111/jch.14011.
Cohen JB, Hanff TC, Corrales-Medina V, William P, Renna N, Rosado-Santander NR, et al. Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol. J Clin Hypertens (Greenwich). 2020 Oct;22(10):1780–8.
Cohen, Jordana B., et al. “Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol.J Clin Hypertens (Greenwich), vol. 22, no. 10, Oct. 2020, pp. 1780–88. Pubmed, doi:10.1111/jch.14011.
Cohen JB, Hanff TC, Corrales-Medina V, William P, Renna N, Rosado-Santander NR, Rodriguez-Mori JE, Spaak J, Andrade-Villanueva J, Chang TI, Barbagelata A, Alfonso CE, Bernales-Salas E, Coacalla J, Castro-Callirgos CA, Tupayachi-Venero KE, Medina C, Valdivia R, Villavicencio M, Vasquez CR, Harhay MO, Chittams J, Sharkoski T, Byrd JB, Edmonston DL, Sweitzer N, Chirinos JA. Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol. J Clin Hypertens (Greenwich). 2020 Oct;22(10):1780–1788.
Journal cover image

Published In

J Clin Hypertens (Greenwich)

DOI

EISSN

1751-7176

Publication Date

October 2020

Volume

22

Issue

10

Start / End Page

1780 / 1788

Location

United States

Related Subject Headings

  • Withholding Treatment
  • Vasoconstrictor Agents
  • Severity of Illness Index
  • SARS-CoV-2
  • Respiration, Artificial
  • Renal Replacement Therapy
  • Prospective Studies
  • Multiple Organ Failure
  • Male
  • Incidence